Enrollment begins for predictive low glucose trial

13:30 EDT 19 Aug 2017 | Healio

Tandem Diabetes Care has announced the enrollment of the first participant in an at-home trial assessing predictive low glucose suspend technology, according to a press release. The trial will assess the safety and efficacy of Tandem’s t:slim X2 insulin pump with predictive low glucose suspend, which suspends insulin delivery when glucose gets to low and resumes delivery when glucose rises. The trial will also use Dexcom’s G5 mobile continuous glucose monitor as part of the delivery system.

Original Article: Enrollment begins for predictive low glucose trial


More From BioPortfolio on "Enrollment begins for predictive low glucose trial"

Quick Search


Relevant Topic

Endocrine Disorders
Endocrine disorders are grouped into two categories: hormone imbalance - when a gland produces too much or too little of an endocrine hormone development of lesions (such as nodules or tumors) in the endocrine system, which may or may not affect...